Showing results (881-890 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|October 8, 2019
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyMyung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, et al.
The Lancet. Oncology|October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
The Lancet. Oncology|January 24, 2021
Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling studySathira Kasun Perera, Susannah Jacob, Brooke E Wilson, et al.
The Lancet. Oncology|January 21, 2021
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trialFrançois Quénet, Dominique Elias, Lise Roca, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
The Lancet. Oncology|February 4, 2021
Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization GroupRenée L Mulder, Anna Font-Gonzalez, Melissa M Hudson, et al.
The Lancet. Oncology|January 15, 2022
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trialDavid Cella, Robert J Motzer, Cristina Suarez, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.
The Lancet. Oncology|January 1, 2022
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancerIcro Meattini, Carlotta Becherini, Liesbeth Boersma, et al.
Pageof 338